NEW YORK — Amprion said on Tuesday that it has received roughly $730,000 in additional funding from the National Institutes of Health to validate its SynTap test for Parkinson's disease and dementia.
The new funding brings the total amount for the project to about $1.6 million, Amprion said in a statement.
The test, launched last year through Amprion's CLIA lab, is designed to detect a-synuclein aggregates to aid in the diagnosis of Parkinson's disease and other brain conditions such as Lewy body dementia, and multiple system atrophy. The test also helps distinguish underlying synucleinopathies in other neurodegenerative conditions, such as Alzheimer's disease.
With the NIH funding, the San Francisco-based company said it will analytically validate the test to establish that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use.
Amprion recently said that it expects to file an application for 510(k) clearance for the SynTap test by the first quarter of 2023.